ライフサイエンスコーパス: placebo

1 the placebo group (P<0.001 for each dose vs. placebo).

2 8 patients (30%) died (78 azithromycin vs 60 placebo).

3 , while AE incidence at 20 ng was similar to placebo.

4 ala and fronto-limbic regions, compared with placebo.

5 igned to escitalopram, 94 to tDCS, and 60 to placebo.

6 de 400 mug (those aged <11 years 200 mug) or placebo.

7 and caudate nucleus iron content compared to placebo.

8 ed to mepolizumab 100 mg and 277 assigned to placebo.

9 progression of diabetic kidney disease than placebo.

10 volume in 1 second (FEV1), as compared with placebo.

11 e dose of MABp1 and 102 at least one dose of placebo.

12 MET; 2) FDIS+placebo; 3) SRP+MET; and 4) SRP+placebo.

13 ril, 31 received bisoprolol, and 30 received placebo.

14 imary end points than did those who received placebo.

15 coconjugates (serotypes Ia, Ib, and III), or placebo.

16 ifference in efficacy between treatments and placebo.

17 ociated with higher adverse event rates than placebo.

18 an 4 times as high with benralizumab as with placebo.

19 s of age compared with children treated with placebo.

20 ear of oral neratinib 240 mg/day or matching placebo.

21 , 30 and 60 mg/kg per infusion) of TNT009 or placebo.

22 ules, the 50-mug patch was not compared with placebo.

23 ere more frequent with tofacitinib than with placebo.

24 amin E, selenium, vitamin E and selenium, or placebo.

25 relapse was lower with lisdexamfetamine than placebo.

26 ts were randomized to tolvaptan 30 mg/day or placebo.

27 <0.0001) for lumacaftor and ivacaftor versus placebo.

28 type 2 diabetes mellitus to canagliflozin or placebo.

29 lihood of response to MEDI2070 compared with placebo.

30 relapse rates in patients given SCIg versus placebo.

31 y and a greater improvement in symptoms than placebo.

32 egimen, and eight (29%) of 28 patients given placebo.

33 es of dofetilide, quinidine, ranolazine, and placebo.

34 vention were randomized to ranolazine versus placebo.

35 125 patients, 62 with eculizumab and 63 with placebo.

36 ea was more common with pertuzumab than with placebo.

37 CS plus escitalopram, or sham tDCS plus oral placebo.

38 mean [95% CI], active, 0.38 [0.26-0.56] vs. placebo, 0.52 [0.35-0.76]; P = 0.18).

39 e treatment with perindopril, bisoprolol, or placebo (1:1:1) for the duration of trastuzumab adjuvant

40 pib once daily (15,225 patients) or matching placebo (15,224 patients).

41 .5 mug) or 2.5 mug (2 puffs of 1.25 mug), or placebo (2 puffs), administered through the Respimat dev

42 reduce BMI z score to a greater extent than placebo (-3.4%; P = 0.09) and a significant -3.8% reduct

43 four treatment groups: 1) FDIS+MET; 2) FDIS+placebo; 3) SRP+MET; and 4) SRP+placebo.

44 %]) than with TMP-SMX (29 of 261 [11.1%]) or placebo (32 of 255 [12.5%]); all adverse events resolved

45 nostril) of LAIV H5N2 (101 participants) or placebo (51 participants) 21 days apart.

46 event occurred for 182 patients assigned to placebo [62%, including early escape patients switched t

47 esponse rate with ipilimumab (23%) than with placebo (8%).

48 DG and overall composite score compared with placebo, accelerated GE, and was generally safe and well

49 pared with a decrease from 14.9 to 14.1 with placebo (adjusted median difference between the cannabid

50 After short-term treatment at week 12, the placebo-adjusted geometric mean ratio of UACR change fro

51 20 mg or 40 mg, according to body weight) or placebo, administered subcutaneously every 2 weeks.

52 (Alliance) 100104 study, lenalidomide versus placebo after autologous stem-cell transplantation (ASCT

53 randomly assigned one to one to lapatinib or placebo after completion of first-line/initial chemother

54 mega 3 polyunsaturated fatty acids alone, or placebo alone.

55 a 3:1 ratio to receive 1200 million cells or placebo and assessed for safety through the first 7 days

56 beta-catenin, or vimentin expression between placebo and R-ketorolac treatment groups.

57 M-CSF alone improves 6-minute walk more than placebo and whether exercise improves 6-minute walk more

58 4.5% from baseline, P<0.01 for all doses vs. placebo) and in levels of triglycerides (reductions of 3

59 the placebo group (P<0.001 for each dose vs. placebo), and everyday-activities scores improved by 5.5

60 received tofacitinib and in one who received placebo, and adjudicated cardiovascular events occurred

61 Three deaths occurred (2 hydroxyurea, 1 placebo, and none from malaria).

62 patients with type 2 diabetes compared with placebo, and showed a similar safety profile to currentl

63 g single crypts were laser microdissected in placebo- and sulindac- treated FAP patient tissue after

64 t rates similar to those of viruses from the placebo arm.

65 eceived tofacitinib and in none who received placebo; as compared with placebo, tofacitinib was assoc

66 ive standards on average at baseline, a mean placebo-associated improvement of less than 0.2 SD provi

67 of long-acting cabotegravir 800 mg or saline placebo at 12 week intervals.

68 ria-endemic Uganda, comparing hydroxyurea to placebo at 20 +/- 2.5 mg/kg per day for 12 months.

69 In conclusion, compared with placebo, bosutinib at 200 mg/d reduced kidney growth in

70 l lenalidomide (2.5 mg/day) or matching oral placebo capsules (2.5 mg/day) for 28-day cycles, until d

71 MN group), iron plus MMNs (Fe+MMN group), or placebo capsules.

72 combined with a 26-week prednisone taper, or placebo combined with a prednisone taper over a period o

73 eristics were associated with improvement in placebo conditions.

74 atients; a phase 3 randomized, double blind, placebo controlled study involving 186 patients; an open

75 (Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effe

76 e disorder were randomly assigned to open or placebo-controlled citalopram treatment.

77 deshi children from 2 previous double-blind, placebo-controlled cluster-randomized trials were revisi

78 igator-initiated, multicenter, single-blind, placebo-controlled crossover clinical trial was conducte

79 nce imaging (fMRI) in a 2-drug, double-blind placebo-controlled crossover design conducted from Janua

80 In a double-blind placebo-controlled crossover design, the immune system i

81 In a randomized, double-blind, placebo-controlled crossover study of individuals with s

82 eanut sensitivity and positive double-blind, placebo-controlled food challenges to an eliciting dose

83 In two double-blind, placebo-controlled immunotherapy studies, 33 patients al

84 underwent a further double-blind crossover, placebo-controlled oral gluten challenge, which had a fi

85 Adverse event incidences in the 24-week placebo-controlled period were similar across groups (at

86 To this end, we combined double-blind, placebo-controlled pharmacology [D2 receptor (D2R) antag

87 This multicenter, double-blind, placebo-controlled RCT was powered on a 5% difference in

88 s, and carried out a double-blind randomized placebo-controlled study for 16 weeks, followed by an op

89 this multicenter, double-blind, randomized, placebo-controlled study, 74 participants with peanut al

90 III, randomized, double-masked, multicenter, placebo-controlled study.

91 This randomized, double-blind, placebo-controlled trial assessed the effects of tenapan

92 Double-blinded, placebo-controlled trial at 9 academic medical centers i

93 ODS AND TIME was a randomized, double-blind, placebo-controlled trial comparing 150 million bone marr

94 h Malaria) was a randomized, double-blinded, placebo-controlled trial conducted in malaria-endemic Ug

95 was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruit

96 nducted a phase 2, randomized, double-blind, placebo-controlled trial in 27 centers across North Amer

97 THOD: This 6-week, randomized, double-blind, placebo-controlled trial included patients with schizoph

98 a double-blind, randomized, parallel-group, placebo-controlled trial of a single ketamine infusion (

99 We thus performed a randomized placebo-controlled trial with atorvastatin 40 mg/day for

100 Patients and Methods In this double-blinded, placebo-controlled trial, patients with HER2-positive ea

101 this multicenter, double-blind, randomized, placebo-controlled trial, we assessed the efficacy and s

102 In this double-blind randomised placebo-controlled trial, we enrolled undiagnosed patien

103 In this randomised, double-blind, placebo-controlled trial, we randomly allocated 172 57 (

104 In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1776 wome

105 a pre-registered, randomised, double-blind, placebo-controlled trial.

106 We report two double-blind, randomised, placebo-controlled trials in adults with chronic non-can

107 found in all four much smaller, randomized, placebo-controlled trials specifically designed to evalu

108 vidence from 28 trials (only 3 of which were placebo-controlled) shows that colchicine, nonsteroidal

109 agnetic resonance imaging in a double-blind, placebo-controlled, crossover design to determine how in

110 nducted a phase I, randomized, double-blind, placebo-controlled, dose-escalating study of BMS-936559,

111 We did a phase 2, randomised, double-blind, placebo-controlled, dose-escalation trial of intravenous

112 phase 3, randomized withdrawal, multicenter, placebo-controlled, double-blind trial.

113 This randomized, double-blind, placebo-controlled, multicenter study evaluated the effe

114 ducted a phase 2, multicenter, double-blind, placebo-controlled, multiple-ascending-dose trial of inc

115 this randomised, double-blind, multicentre, placebo-controlled, non-inferiority trial, HIV-1-infecte

116 Using a double-blind, randomized, placebo-controlled, parallel design, we tested the effic

117 In this 12-week, double-blind, placebo-controlled, parallel-group trial, 401 participan

118 this multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, 93 EoE patient

119 The study was a 12-week, double-blind, placebo-controlled, phase 2 trial of patients with alkal

120 In this 1-year, randomised, double-blinded, placebo-controlled, phase 3 study (LIBERTY AD CHRONOS),

121 We did a multicentre, randomised, placebo-controlled, phase 3 trial (TACE 2) in 20 hospita

122 is a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial done in 97 centres in

123 In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients

124 We did a double-blind, multicentre, placebo-controlled, randomised withdrawal phase 2a trial

125 Rigorous double-blind, placebo-controlled, randomized controlled trials, using

126 Multicenter, placebo-controlled, randomized trial (July 2013 to final

127 This phase 2, randomised, double-blind, placebo-controlled, single-centre, crossover trial asses

128 The primary outcome was placebo-corrected 24-h systolic ambulatory blood pressur

129 or 12 weeks, then three rounds of 8 weeks of placebo daily followed by 12 weeks of 150 mg vismodegib

130 or 24 weeks, then three rounds of 8 weeks of placebo daily followed by 8 weeks of 150 mg vismodegib d

131 ell activation, to a greater extent than did placebo (decrease of 2.02+/-2.32 vs. 0.56+/-1.39 ng per

132 gle dose of oral dexamethasone compared with placebo did not increase the proportion of patients with

133 s110402 found that response to GSK561679 and placebo did not significantly differ by genotype alone.

134 000 IU (2.5 mg) colecalciferol or equivalent placebo dosing.

135 et treatment (aspirin/clopidogrel vs aspirin/placebo; double-blinded).

136 k of efficacy could be due to a considerable placebo effect; insensitivity of scales to quantify stif

137 tion-the self in context-that is crucial for placebo effects.

138 Relative to placebo, evolocumab treatment significantly reduced the

139 ived rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurre

140 atin plus nintedanib (200 mg twice daily) or placebo followed by nintedanib plus placebo monotherapy

141 speridone for 16 weeks followed by switch to placebo for 16 weeks, or to receive placebo for 32 weeks

142 witch to placebo for 16 weeks, or to receive placebo for 32 weeks.

143 daily or 1, 3, 10, or 30 mg twice daily) or placebo for 4 weeks.

144 capsule of resveratrol, 125 mg or 500 mg, or placebo for 6 months.

145 orally twice daily) for 90 days followed by placebo for 60 days (group 1), or placebo for 90 days fo

146 ollowed by placebo for 60 days (group 1), or placebo for 90 days followed by clemastine fumarate (5.3

147 study, risankizumab was more effective than placebo for inducing clinical remission in patients with

148 d directional favorability of tolvaptan over placebo for the primary endpoint compared with patients

149 ime and ocular bulbar redness, compared with placebo, for both forms of omega-3 EFAs.

150 ive aspirin, at a dose of 150 mg per day, or placebo from 11 to 14 weeks of gestation until 36 weeks

151 ater in the angiotensin II group than in the placebo group (-1.75 vs. -1.28, P=0.01).

152 i was noted in the vaccine compared with the placebo group (0.149 mean episodes vs 0.146 mean episode

153 ere similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 pati

154 idence interval [CI], 4.08-6.14) than in the placebo group (6.91; 95% CI, 5.82-8.21; P = .03).

155 he prednisolone group and 2.16 points in the placebo group (adjusted difference, -0.20; 95% CI, -0.40

156 min D3 + calcium group and 64 (5.58%) in the placebo group (difference, 1.69% [95% CI, -0.06% to 3.46

157 ed in the idelalisib group compared with the placebo group (grade >/=3 infections and infestations: 8

158 group and in 85 of 158 patients (54%) in the placebo group (hazard ratio, 0.78; 95% CI, 0.57 to 1.07;

159 .2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interv

160 sib group versus 4.0 months (3.1-5.2) in the placebo group (HR 0.76 [0.60-0.97], one-sided p=0.014).

161 numab-treated group (n = 5 of 7) than in the placebo group (n = 0 of 13).

162 ectively, as compared with 2.4 points in the placebo group (P<0.001 for each dose vs. placebo), and e

163 ectively, as compared with 3.3 points in the placebo group (P<0.001 for each dose vs. placebo).

164 cid group and in 2.8% of the patients in the placebo group (P=0.001), and seizures occurred in 0.7% a

165 ) more in the elamipretide group than in the placebo group (P=0.11).

166 ypothyroid Symptoms score (0.2+/-15.3 in the placebo group and 0.2+/-14.4 in the levothyroxine group;

167 months was similar in each group (50 in the placebo group and 61 in the vaccine group).

168 Five women died in the placebo group and three died in the vaccine group.

169 ance was slowed 4 hours postchallenge in the placebo group but not in the gammaT treatment group.

170 One patient in the placebo group died (unrelated to study treatment).

171 roup, 3 in the high-dose group, and 1 in the placebo group discontinued the trial regimen because of

172 hospitalizations was similar in the IIV and placebo group for infants >3 months of age.

173 erence between the cannabidiol group and the placebo group in change in seizure frequency, -22.8 perc

174 rence between the levosimendan group and the placebo group in rates of hypotension or cardiac arrhyth

175 noncardiomyocytes (p = 0.0002) than did the placebo group in some regions of the heart.

176 k 6 in the 80 mg/day group compared with the placebo group on the Abnormal Involuntary Movement Scale

177 s, improvement persisted in 1 patient in the placebo group versus 3 of 4 in the rituximab group, wher

178 trimethoprim-sulfamethoxazole group and the placebo group was similar (mean [SD] change in weight-fo

179 raglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on trea

180 ndetanib group) or placebo plus gemcitabine (placebo group) according to pre-generated sequences prod

181 e brexanolone group vs three patients in the placebo group) and somnolence (two vs none).

182 arib group vs two [2%] of 99 patients in the placebo group), fatigue or asthenia (eight [4%] vs two [

183 the masitinib group vs one [2%] of 63 in the placebo group), rash (four [6%] vs none), and asthenia (

184 , 130 in the topiramate group, and 66 in the placebo group).

185 ized (146 to the active group and 138 to the placebo group).

186 l, we randomly allocated 172 57 (33%) to the placebo group, 57 (33%) to the low-dose group, and 58 (3

187 80 mg/day group, compared with -0.1 for the placebo group, a significant difference.

188 However, in the placebo group, but not in the propranolol group, memory

189 as 27% lower in the active group than in the placebo group, but this did not reach significance (esti

190 ious adverse events: one (2%) patient in the placebo group, three (5%) in the low-dose group, and two

191 common in the canakinumab groups than in the placebo group.

192 e in quality of life score compared with the placebo group.

193 roup became nonreactive to CPT vs 18% in the placebo group.

194 e common in the pregabalin group than in the placebo group.

195 ificantly higher in the VD group than in the placebo group.

196 igned to the minocycline group and 70 to the placebo group.

197 ore common in the imatinib group than in the placebo group.

198 SVG-ZEBOV-GP group, and in 59 (11.8%) in the placebo group.

199 e buparlisib group and 37 (47%) of 78 in the placebo group.

200 lower in the sotagliflozin group than in the placebo group.

201 laparib group and eight (8%) patients in the placebo group.

202 score, 0 in the sertraline group vs 0 in the placebo group; between-group difference, 0 [95% CI, -10.

203 up and 0.060 (95% CI, 0.048 to 0.076) in the placebo group; P = .06.

204 parlisib group versus 23 (16%) of 140 in the placebo group; the most frequent serious adverse events

205 1 year were similar between the ramipril and placebo groups (162.1 +/- 70.5 mm(3) vs. 177.3 +/- 94.3

206 Vitamin D and placebo groups did not differ in change in insulin sensi

207 abnormalities between the PfSPZ Vaccine and placebo groups, and only grade 1 (mild) local or systemi

208 anges occurred within the anakinra 2-week or placebo groups.

209 ff, 104 patients (22%; 54 azithromycin vs 50 placebo) had experienced an airflow decline; 138 patient

210 ared pain modulation through treatment cues (placebo hypoalgesia, treatment context) with pain modula

211 ne expression compared with macrophages from placebo-implanted littermates.

212 million bone marrow mononuclear cells versus placebo in 120 patients with anterior ST-segment-elevati

213 was a randomized trial of evolocumab versus placebo in 27 564 patients with atherosclerotic disease

214 least squares mean difference compared with placebo in absolute change in ppFEV1 from all on-treatme

215 ast cancer treated with either pertuzumab or placebo in addition to trastuzumab and docetaxel.

216 fections was greater with empagliflozin than placebo in all subgroups by UACR status.

217 anezumab did not show efficacy compared with placebo in patients with ALS.

218 ving immediate treatment and those receiving placebo in the deferred treatment group.

219 k factor and glycaemic control (single-blind placebo in the final month).

220 crease of 3.8%) compared with children given placebo (increase of 0.5%, increase of 0.05%, and decrea

221 l injection of gentamicin solution (8 mg) or placebo into 2 intact skin sites for 2 days in 4 of 5 pa

222 on in exacerbations with FF/VI compared with placebo, irrespective of a history of exacerbations or b

223 mine if testosterone treatment compared with placebo is associated with improved verbal memory and ot

224 Compared with placebo, l-methylfolate increased plasma methylfolate le

225 nalidomide-dexamethasone (IRd) compared with placebo-lenalidomide-dexamethasone (placebo-Rd).

226 aily) or placebo followed by nintedanib plus placebo monotherapy until progression.

227 with the last month of leuprolide alone, the placebo month, and the second and third months of estrad

228 g (n = 14) or 4 mg/kg (n = 14) or received a placebo (n = 2/dosing group).

229 y subcutaneous anakinra, 100 mg (n = 25), or placebo (n = 25) for 4 weeks and were followed for an ad

230 allergy (ages 4-25 years) were treated with placebo (n = 25), Viaskin Peanut 100 mug (VP100; n = 24)

231 0 mg of dexamethasone (n = 293) or identical placebo (n = 283).

232 ned to either the interventional (n = 48) or placebo (n = 49) group; 9 infants were exclusively breas

233 ed to receive either lenalidomide (n=231) or placebo (n=229).

234 o receive intra-aortic MSCs (AC607; n=67) or placebo (n=68).

235 Placebo (nitrogen) or inhaled nitric oxide initiated at

236 e of three groups in blocks of 15 to receive placebo (normal saline), low-dose ketamine (0.5 mg/kg),

237 quency was 43% with cannabidiol and 27% with placebo (odds ratio, 2.00; 95% CI, 0.93 to 4.30; P=0.08)

238 oic acid), the multidomain intervention plus placebo, omega 3 polyunsaturated fatty acids alone, or p

239 or Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myoca

240 e the effect of subcutaneous anakinra versus placebo on fatigue severity in female patients with CFS.

241 tly greater reduction in anxiety relative to placebo on the LSAS (Time x Treatment: F9,115=2.6, p=0.0

242 , rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg an

243 oral cabotegravir 30 mg tablets or matching placebo once daily during a 4 week oral lead-in phase, f

244 =2.0) were assigned randomly to groups given placebo or 100, 300, 450, 600, or 900 mg latiglutenase d

245 ion, or harms of systemic medications versus placebo or another intervention.

246 , patients were randomly assigned to receive placebo or hydrocortisone (0.5 mg/kg twice per day for 7

247 to receive 12 weeks of blind treatment with placebo or MABp1, a true human antibody targeting IL-1al

248 of invasive fungal infections compared with placebo or no intervention in critically ill patients wi

249 e lenalidomide group and 23.5 months for the placebo or observation group (hazard ratio, 0.48; 95% CI

250 enalidomide maintenance group and 603 in the placebo or observation group).

251 SCT in patients with NDMM when compared with placebo or observation.

252 n with a history of myocardial infarction to placebo or one of three doses of canakinumab (50 mg, 150

253 in two randomized treatment periods of daily placebo or PF-04958242 for 5 days separated by a washout

254 l significance of the study drug compared to placebo ( P < 0.0161 and P < 0.0001, respectively).

255 nide (0 [range, 0-2] vs 2.5 [range, 0-4] for placebo; P < .01), with complete suppression observed in

256 significant difference was seen between the placebo patch vs the 100-mug patch.

257 randomized to 21 mg nicotine (TNP; n=37) or placebo (PBO; n=43) transdermal patch following overnigh

258 allocated ramucirumab plus docetaxel versus placebo plus docetaxel (median 4.07 months [95% CI 2.96-

259 tanib plus gemcitabine (vandetanib group) or placebo plus gemcitabine (placebo group) according to pr

260 eated patients than in patients treated with placebo plus topical corticosteroids.

261 costeroids vs 12% [39 patients] who received placebo plus topical corticosteroids; p<0.0001) and EASI

262 -line oral buparlisib (100 mg once daily) or placebo, plus intravenous paclitaxel (80 mg/m(2) on days

263 us injection of either mepolizumab 100 mg or placebo, plus standard of care, every 4 weeks for 24 wee

264 (0.65, 0.56 to 0.75) remained lower than the placebo rate in TRAFFIC and TRANSPORT.

265 PFS was improved with IRd vs placebo-Rd in both high-risk and standard-risk cytogenet

266 red with placebo-lenalidomide-dexamethasone (placebo-Rd).

267 ncidence of adverse events among vaccine and placebo recipients throughout the study.

268 genetic sequence of viruses from vaccine and placebo recipients to the sequence of the vaccine itself

269 age 4 months to receive whole-egg powder or placebo (rice powder) until 8 months of age, with all ot

270 assigned patients to receive tDCS plus oral placebo, sham tDCS plus escitalopram, or sham tDCS plus

271 Mepolizumab versus placebo showed significant improvements at week 24 from

272 tive voice-response system to eltrombopag or placebo, stratified by baseline platelet count (<10 x 10

273 ne were not more likely than those receiving placebo to have complete symptom resolution.

274 none who received placebo; as compared with placebo, tofacitinib was associated with increased lipid

275 eight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy.

276 aive cells, while the opposite occurred with placebo-treated IH-exposed mice.

277 ped normal glucose tolerance compared with 8 placebo-treated participants (16.0%) (P < .001; number n

278 Finally, as with many trials, some placebo-treated participants showed improvement on the S

279 %) eltrombopag-treated patients and 32 (68%) placebo-treated patients.

280 hole blood samples from both omalizumab- and placebo-treated subjects.

281 hile a similar interaction was observed with placebo treatment, treatment with estradiol attenuated t

282 05) up to 2 days after surgery compared with placebo treatment.

283 cluding tissue-resident cells, compared with placebo treatment.

284 to rifaximin 550 mg twice a day (n = 36) or placebo twice a day (n = 18).

285 o aspirin once a day (100 mg and rivaroxaban placebo twice a day).

286 ere randomized to receive either BOS 2 mg or placebo twice daily for 12 weeks.

287 ses were 0, 43, and 130 mg of protein in the placebo, VP100, and VP250 groups, respectively (placebo

288 cebo, VP100, and VP250 groups, respectively (placebo vs VP100, P = .014; placebo vs VP250, P = .003).

289 s, respectively (placebo vs VP100, P = .014; placebo vs VP250, P = .003).

290 t with testosterone for 1 year compared with placebo was not associated with improved memory or other

291 ned to BIIB074 versus nine (64%) assigned to placebo were classified as treatment failures (p=0.0974)

292 Only patients randomized to placebo were considered.

293 Changes in both seladelpar groups versus placebo were significant (p<0.0001 for both groups vs pl

294 t severe adverse events (>4% difference from placebo) were diarrhoea (eight [11%] of 70 in the masiti

295 carbose (50 mg three times a day) or matched placebo, which was added to standardised cardiovascular

296 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority

297 administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiori

298 The least-squares mean difference versus placebo with respect to the absolute change in the perce

299 ere significant (p<0.0001 for both groups vs placebo), with no significant difference between the two

300 the most common local adverse events versus placebo within the first 14 days were arm pain (57.4% [2